Corneal confocal microscopy is helpful in VKC

Article

Corneal confocal microscopy is useful for studying in vivo pathologic corneal changes in vernal keratoconjunctivitis (VKC).

Corneal confocal microscopy is useful for studying in vivo pathologic corneal changes in vernal keratoconjunctivitis (VKC), claims a study in the journal Ophthalmology.

Dr Andrea Leonardi et al., Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy, completed a prospective, comparative case study on 32 patients with VKC and 40 normal participants.

All patients underwent a full ophthalmic examination and central cornea images were gathered using a x40 non-contact lens and a Z-ring device. The main outcome measures were the superficial and basal epithelium, subbasal nerve plexus, anterior stroma, stromal nerves and endothelium of the central cornea.

It was discovered that the VKC patients had increased diameter, reflectivity and presence of nuclear activation of superficial epithelial cells. They also had a reduced basal membrane density, an increased presence of activated keratocytes and inflammatory cells in the anterior stroma.

The VKC patients also presented with lower density and number of fibres, lower number of beadings and a higher grade of tortuosity of fibres in the subbasal nerve plexus. In the stromal corneal nerves there was an increased thickness, deflections and tortuosity changes.

The study authors concluded that the changes in the epithelium and subbasal and stromal corneal nerves could be linked to tear dysfunction and non-specific hyperactivity.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.